Jie Ding

US Patent:

20070154546, Jul 5, 2007

Filed:

Dec 30, 2005

Appl. No.:

11/322480

Inventors:

Jack Zhang - Diamond Bar CA, US
Mary Luo - Diamond Bar CA, US
Richard Li - Alhambra CA, US
Jie Ding - Fontana CA, US

International Classification:

A61K 31/727
A61K 9/22
A61K 31/22
A61K 31/44

US Classification:

424468000, 514056000, 514546000, 514358000

Abstract:

The present invention relates to a pharmaceutical composition comprising a salt of quaternary ammonium of an acid drug in the form of a suspension or an emulsion, suitable for parenteral administration and providing a sustained release of the drug. In one preferred embodiment, the present invention is directed to a long term sustained release composition for parenteral administration, comprising a salt of heparin or low molecular weight heparin in an emulsion with a salt of acylcholine, for the prevention and treatment of venous thrombosis and pulmonary embolism.

US Patent:

20080153784, Jun 26, 2008

Filed:

Jun 25, 2007

Appl. No.:

11/768181

Inventors:

Jack Yongfeng Zhang - Diamond Bar CA, US
Mary Ziping Luo - Diamond Bar CA, US
Dingyuan Fei - Montclair CA, US
Kevin Xie - Anaheim CA, US
Jie Fei Ding - Riverside CA, US

International Classification:

A61K 31/663
A61P 19/10

US Classification:

514108

Abstract:

Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis.

US Patent:

20230076626, Mar 9, 2023

Filed:

Oct 28, 2022

Appl. No.:

17/975924

Inventors:

- Rancho Cucamonga CA, US
Mary Zi-ping Luo - Diamond Bar CA, US
Fonda SU - Hacienda Heights CA, US
Marvin Lin - Temple City CA, US
Jie Fei Ding - Diamond Bar CA, US
Justin Jun Wei - Chino Hills CA, US
Wenbo Yu - Arcadia CA, US
Rong Zhou - Brea CA, US

International Classification:

A61K 31/137
A61K 9/00
A61K 47/18
A61K 47/12
A61K 47/02

Abstract:

Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 μg/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25 C.2 C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

US Patent:

20150157649, Jun 11, 2015

Filed:

Feb 13, 2015

Appl. No.:

14/622746

Inventors:

- Rancho Cucamonga CA, US
Mary Ziping Luo - Diamond Bar CA, US
Dingyuan Fei - Montclair CA, US
Kevin Xie - Anaheim CA, US
Jie Fei Ding - Riverside CA, US

International Classification:

A61K 31/663
A61K 9/00

Abstract:

Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis.

US Patent:

20150157650, Jun 11, 2015

Filed:

Feb 13, 2015

Appl. No.:

14/622749

Inventors:

- Rancho Cucamonga CA, US
Mary Ziping Luo - Diamond Bar CA, US
Dingyuan Fei - Montclair CA, US
Kevin Xie - Anaheim CA, US
Jie Fei Ding - Riverside CA, US

International Classification:

A61K 31/663

Abstract:

Pharmaceutical compositions for long-term sustained release of bisphosphonate drugs are provided. In one embodiment, the composition includes an aqueous suspension of a solid which includes a salt of a bisphosphonate drug and a salt of pentavalent phosphorus oxoacid. The compositions can be used to treat a variety of bone diseases, including osteoporosis.